RBA Wealth Management LLC Has $4.84 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

RBA Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,331 shares of the medical instruments supplier’s stock after acquiring an additional 604 shares during the period. Becton, Dickinson and Company comprises about 1.8% of RBA Wealth Management LLC’s portfolio, making the stock its 23rd largest position. RBA Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $4,839,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of BDX. S.A. Mason LLC grew its position in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after buying an additional 50 shares during the period. Oregon Pacific Wealth Management LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at $244,000. U.S. Capital Wealth Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 14.3% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 1,224 shares of the medical instruments supplier’s stock valued at $278,000 after buying an additional 153 shares during the last quarter. Golden State Equity Partners grew its holdings in shares of Becton, Dickinson and Company by 801.1% in the fourth quarter. Golden State Equity Partners now owns 1,622 shares of the medical instruments supplier’s stock worth $368,000 after acquiring an additional 1,442 shares during the period. Finally, SYM FINANCIAL Corp purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $201,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BDX shares. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock worth $2,210,716 in the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $247.57 on Tuesday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The stock has a market capitalization of $71.80 billion, a price-to-earnings ratio of 41.68, a PEG ratio of 1.80 and a beta of 0.40. The firm has a fifty day simple moving average of $230.53 and a 200-day simple moving average of $233.83. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.68%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.